BIOZOL TRANSDERMAL SERUM
Live / Registered — Registered — Section 8 accepted (as of 18 Sept 2026)
What this means for you
Registered since 13 Oct 2020. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 13 Oct 2030: the §8 & §9 renewal).
Record
- Serial number
- 87316486
- Registration number
- 6175489
- Mark type
- Word mark
- Filed
- 27 Jan 2017
- Published for opposition
- 04 Jul 2017
- Registered
- 13 Oct 2020
- Next maintenance filing
- §8 & §9 renewal, due by 13 Oct 2030 (grace period to 13 Apr 2031)
- Attorney of record
- Sean B. MacKenzie
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical formulation for transcutaneous drug delivery for the treatment of acne, fungal infections, gout, diaper rash, skin infections, shingles, dandruff, eczema, psoriasis, seborrheic dermatitis, arthritis, joint inflammation, pain, fever blisters, cold sores, insect bites, stings, poison ivy, poison oak, and poison sumac
Owner
- Nexzol Pharma, Inc., San Clemente, CA, US
- Nexzol Pharma, Inc., San Clemente, CA, US
- Nuremedy Pharma LLC, Las Vegas, NV, US
- Nuremedy Pharma LLC, Las Vegas, NV, US
Prosecution history
- 18 Sept 2026 — NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
- 18 Sept 2026 — REGISTERED - SEC. 8 (6-YR) ACCEPTED
- 17 Sept 2026 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 17 Jul 2026 — TEAS SECTION 8 RECEIVED
- 13 Oct 2025 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 13 Oct 2020 — REGISTERED-PRINCIPAL REGISTER
- 11 Sept 2020 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 10 Sept 2020 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 24 Aug 2020 — STATEMENT OF USE PROCESSING COMPLETE
- 18 Aug 2020 — USE AMENDMENT FILED
- 18 Aug 2020 — TEAS STATEMENT OF USE RECEIVED
- 08 Jan 2020 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Jan 2020 — SOU EXTENSION 5 GRANTED
- 12 Dec 2019 — SOU EXTENSION 5 FILED
- 26 Jul 2019 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED